Beneficial value of [18F]FDG PET/CT in the follow-up of patients with stage III non-small cell lung cancer (NVALT31-PET study): study protocol of a multicentre randomised controlled trial

Introduction Patients with stage III non-small cell lung cancer (NSCLC) are at high risk of developing post-treatment recurrences (50–78%) during follow-up. As more effective treatments are now available, especially for patients with oligometastatic disease, earlier detection of recurrences may prol...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wietske Kievit, C Jacobs, S Teerenstra, W Kievit, Steven Teerenstra, M de Vries, Iris Walraven, S R Rutgers, Colin Jacobs, J W G van Putten, Nicole E Billingy, Annemarie Becker-Commissaris, Idris Bahce, M Youssef, Cornelia A Verberkt, Suresh Senan, Marloes J Hassing, Joran Schoorlemmer, Merve Sarioglu, Erik H J G Aarntzen, Emile F I Comans, Astrid Keijser, Michel M van den Heuvel, N C van Walree, C J van Loenhout, Y Berk, R C Boshuizen, K J G Schulkes, M van Laren, M Schiefer, J Dits, E Lammers, E J Geraedts, K W Maas, P Brocken, A C M Mulders, S C van ‘t Westeinde, E Citgez, J N A van Diessen, E A Kastelijn, M A Kroeze, J M W van Haarst, A S R Lindert, I Bahce, S Senan, E F I Comans, N E Billingy, C A Verberkt, M Hassing, J Schoorlemmer, E H J G Aarntzen, M M van den Heuvel, I Walraven, A Becker-Commissaris
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-07-01
Series:	BMJ Open
Online Access:	https://bmjopen.bmj.com/content/15/7/e103745.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Beneficial value of [18F]FDG PET/CT in the follow-up of patients with stage III non-small cell lung cancer (NVALT31-PET study): study protocol of a multicentre randomised controlled trial

Similar Items